Metastatic neoplasm

This early-phase trial tests a new mRNA vaccine called PAN-NeoVax, designed by artificial intelligence to target multiple cancer types. The vaccine is injected directly into tumors in 9 patients with advanced solid cancers who have run out of standard options. The main goal is to…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…

This study tests a high dose of the chemotherapy drug methotrexate given through a vein in people with breast cancer that has spread to the lining of the brain. The goal is to see if it helps them live longer. The trial includes adults with triple-negative, HER2-positive, or horm…

This early-stage trial tests a new drug called HLX48 in 72 people with advanced or metastatic solid tumors that have not responded to standard treatments. HLX48 is designed to target two cancer-related proteins (EGFR and c-MET) and deliver a toxic payload directly to cancer cells…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This early-stage trial tests whether giving a higher dose of focused radiation (stereotactic radiosurgery) to brain metastases is safe. About 50 people with 1 to 5 brain tumors who have never had brain radiation will receive an experimental dose on one tumor, while other tumors g…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This study tests an experimental drug called HRX215 in people who had part of their liver removed because colon cancer spread there. The drug is meant to help the liver grow back and work better after surgery. About 80 adults will take either HRX215 or a placebo for 28 days, and …

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer …

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the best dose and check if it is safe and shrinks tumors. All participants get the drug by injection, and the study invol…

This Phase II trial is testing a combination of three drugs—zanidatamab, pembrolizumab, and chemotherapy—in 80 people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer fr…

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This expanded access program provides vepugratinib, an oral drug, to people with metastatic urothelial carcinoma or other solid tumors that have a specific FGFR3 genetic change. Participants must have exhausted other approved treatments, including erdafitinib for bladder cancer, …

This early-phase trial tests an antibiotic called novobiocin in people with advanced solid tumors that have specific DNA repair mutations (like BRCA). The drug blocks a protein cancer cells use to fix their damaged DNA, which may cause them to die. The study aims to find the safe…

This early-stage trial is testing an experimental drug called RO7566802, alone or with the immunotherapy atezolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of activity. Ab…

This study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…

This trial tests a precise type of radiation called SABR on all visible tumors in people with 11 or more metastases. Participants are randomly assigned to either standard palliative radiation or SABR to every tumor. The goal is to see if this aggressive approach improves overall …

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…

This early-stage study tests a personalized radiation technique called PULSAR for lung cancers located near the center of the chest. The goal is to make treatment safer while still effectively controlling the tumor. About 30 adults with primary or metastatic lung cancer will rece…

This early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This study tests whether giving focused radiation (radiosurgery) before surgically removing brain metastases can prevent the tumors from coming back. About 36 adults with 1 to 4 brain metastases will receive radiosurgery followed by surgery. Researchers will also monitor side eff…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This phase III trial tests whether proton craniospinal irradiation (pCSI) can improve survival compared to standard involved-field radiation therapy (IFRT) for patients with breast or non-small cell lung cancer that has spread to the lining of the brain and spinal cord (leptomeni…

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and CDK4/6 inhibitors can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal i…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…

This Phase 3 trial tests whether a combination of two immunotherapy drugs (botensilimab and balstilimab) can help people with advanced stomach cancer live longer compared to standard treatment. The study includes 132 adults whose tumors have a specific genetic marker (MSI-H/dMMR)…

This study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This study tests whether removing as much tumor as possible through surgery before giving a targeted radioactive drug (Lutetium Lu 177 dotatate) works better for people with slow-growing neuroendocrine tumors that have spread to the liver. Six adults with grade 1 or 2 tumors will…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study is for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. Researchers want to see if adding a precise, one-time radiation treatment (SRS) to the standard drug osimertinib is better than the drug alone at controlling brain tumor…

This study is for people whose brain metastases have come back or caused radiation damage after initial treatment. It compares a laser-based procedure (LITT) plus standard care against standard care alone (steroids or repeat radiation). The goal is to see if LITT can better contr…

This early-phase study tests a new drug called ISM3412 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety and find the best dose. About 80 participants will take part in two stages: first to find…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-phase trial tests a personalized treatment for people with metastatic solid tumors that have a specific genetic change called KRAS G12V. The patient's own immune cells (T cells) are collected, genetically modified to recognize and attack cancer cells carrying the KRAS …

This early-stage study tests a combination of two drugs—trastuzumab deruxtecan and azenosertib—in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and check for…

This phase II trial is testing whether three antibody-drug conjugates (ADCs) can shrink advanced or metastatic solid tumors that have high levels of specific proteins (Trop-2, nectin-4, or HER2). About 500 patients will first have their tumors tested for these markers, then recei…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…

This phase 3 trial is testing whether adding a chemotherapy pump that delivers drugs directly to the liver (hepatic arterial infusion, or HAI) can help people with colorectal cancer that has spread to the liver and cannot be removed by surgery. About 408 participants will receive…

This early-phase study tests the safety and best dose of two drugs, ZEN003694 and abemaciclib, given together. It is for people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the combinatio…

This study tests whether a focused ultrasound device can safely open the blood-brain barrier in people with non-small cell lung cancer that has spread to the brain. About 30 participants will receive standard immunotherapy plus the ultrasound procedure. The goal is to see if this…

This phase 2 trial is testing a type of radiation called craniospinal irradiation that avoids the hippocampus, a brain area key for memory. It is for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if …

This early-stage trial is testing whether combining two drugs—niraparib and irinotecan—can safely treat advanced solid tumors that have mutations in DNA repair genes like BRCA. The study will enroll 24 adults with various cancers, including breast, ovarian, pancreatic, and others…

This study tests whether combining radiation therapy with three drugs (platinum chemotherapy, adebrelimab, and bevacizumab) can control brain metastases from triple-negative breast cancer. About 58 adults aged 18-70 with this specific type of advanced breast cancer will receive t…

This early-stage trial is testing a new oral drug called LOXO-435, alone or with other cancer medicines, in people with advanced solid tumors that have a specific change in the FGFR3 gene. The study aims to find the right dose and check for safety and early signs of effectiveness…

This study tests whether a combination of two drugs (ZEN003694 and talazoparib) can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 88 adults will take part. Researchers will also look at participants' genes to see if…

This early-phase trial is testing two experimental drugs, peposertib and tuvusertib, together in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and to understand side effects. About 66 participants wi…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This study tests whether adding the experimental drug CGT9486 to the standard drug sunitinib helps people with advanced GIST live longer without their cancer growing. About 482 adults with GIST that cannot be removed by surgery or has spread will take part. The goal is to see if …

This phase 2 trial is testing three different drugs—abiraterone acetate, enzalutamide, and apalutamide—in 192 veterans with castrate-sensitive prostate cancer that has spread. The goal is to see which drug works best as a first treatment when combined with hormone therapy. Resear…

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This study tests whether adding targeted radiation to immunotherapy can help control advanced non-small cell lung cancer better than standard chemotherapy. It is for patients whose cancer has worsened after previous immunotherapy. About 39 adults will be randomly assigned to one …

This study looks at whether giving focused radiation before or after surgery works better for people with brain tumors that started elsewhere in the body. About 140 adults with one brain tumor that can be removed will be randomly assigned to get radiation either before or after s…

This large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to better fight the cancer. Th…

This early-phase trial tests a combination of two drugs—temozolomide and M1774—in people with advanced solid tumors that have spread. Temozolomide damages cancer cell DNA, while M1774 blocks enzymes that help cancer grow. The goal is to find the best dose and see if the combo can…

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This early-phase trial is testing whether a new drug called ZEN003694, when added to the chemotherapy capecitabine, is safe for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 participants will receive the combination to find the best d…

This early-stage trial is testing an experimental drug called CHS-114 combined with the immunotherapy toripalimab, with or without standard chemotherapy, in 154 people with advanced or metastatic solid tumors. The main goal is to see if the combination is safe and to get an early…

This study is for people with stage IV cancer that has started to grow in only a few places (oligoprogression). It compares adding local treatments like radiation or surgery to all growing spots versus switching to a new systemic therapy. The goal is to see if this approach can b…

This early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…

This study looks at whether adding a new anti-tumor drug to standard radiation therapy can help control advanced breast cancer that has spread to the brain. About 100 adults with this condition will be observed to see how long the cancer stays under control and if the treatment i…

This study tests a new treatment for people with stage IV melanoma that has spread to the brain. It combines a chemotherapy drug (temozolomide) with specially grown immune cells (NK cells) from a healthy donor. The goal is to see if this combination is safe and can shrink brain t…

This phase II trial is testing the drug pemetrexed in people with advanced bladder cancer or other solid tumors that have spread and carry certain gene mutations (MLL4, UTX, or MTAP). The goal is to see if pemetrexed can shrink tumors. About 64 participants will receive the drug …

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…

This study tests a new immunotherapy for people with advanced HPV-related cancers, such as cervical, throat, anal, and penile cancers. Participants receive specially engineered immune cells designed to attack cancer cells carrying the HPV16 virus. The goal is to see if this treat…

This study tests a new treatment using specially engineered natural killer (NK) cells to attack advanced lung cancer that has spread. About 60 adults whose tumors have certain markers will receive chemotherapy followed by an infusion of these cells. The goal is to find a safe dos…

This early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgica…

This phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…

This study tests whether stereotactic radiosurgery (SRS), a precise form of radiation, can effectively treat brain metastases in people newly diagnosed with small cell lung cancer that has spread to the brain. About 62 participants will receive SRS, and researchers will track how…

This early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find th…

This phase III trial is for people with 5 to 15 brain metastases from cancers that are not blood cancers. It compares two treatments: stereotactic radiosurgery (SRS), which delivers high-dose radiation to small spots in one or two days, versus whole brain radiation that avoids th…

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…

This early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks DNA repair in cancer ce…

This study tests a new experimental drug, DB-1419, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 360 participants will ta…

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…

This early-phase study is testing whether a dietary supplement called zeaxanthin, taken alone or with the immunotherapy drug pembrolizumab, is safe for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 72 participants to find …

This study tests two different chemotherapy combinations for people with metastatic colorectal cancer that has spread and needs a second treatment. About 280 adults will be randomly assigned to receive either FOLFIRI or irinotecan, with or without bevacizumab. The goal is to see …

This early-phase trial is testing a new type of cell therapy for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered natural killer (NK) cells that target two proteins found on cancer cells. Up to 42 part…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This early-phase trial tests a radioactive drug called Y-NM600 in people with metastatic cancer who are already receiving immunotherapy (anti-PD-1 or anti-PD-L1). The goal is to see if adding Y-NM600 is safe and can make the immunotherapy work better. Up to 60 participants will b…

This study tests an experimental drug called NEOK002 in people with advanced solid tumors that have spread and cannot be removed by surgery. The drug is designed to target two proteins on cancer cells to deliver a toxic payload. The study has two parts: first, finding the safest …

This study tests whether a combination of two drugs, sacituzumab tirumotecan and bevacizumab, can shrink or control brain tumors in people with triple-negative breast cancer that has spread to the brain. About 24 adults whose cancer cannot be removed by surgery or radiation will …

This early-stage trial is testing the drug sacituzumab govitecan in 30 people with advanced solid tumors who also have moderate liver impairment. The main goal is to find a safe starting dose by monitoring side effects and how the drug moves through the body. Participants receive…

This early-phase study tests a new radioactive drug (BRP-020063) in 10 people with advanced solid tumors that have spread. The drug is used first for imaging to find tumors, then a low dose is given to see if it's safe and how it travels in the body. The goal is to gather informa…

This study combines two treatments—laser heat to destroy tumors near the spinal cord and precise radiation—to better control spine tumors that have spread from other cancers. About 60 adults with solid tumors will receive both therapies. The goal is to improve tumor control, redu…

This early-phase trial tests an experimental drug called BSI-082, alone or combined with a standard cancer drug (T-DXd), in 57 adults with advanced or metastatic solid tumors that have not responded to other treatments. The study has two parts: first, finding the safest dose of B…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This study is testing whether artificial intelligence (AI) can help doctors choose the right radiation dose for people with lung cancer or tumors that have spread to the lung. The treatment uses a precise type of radiation called SBRT, and the AI aims to personalize the dose to e…

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…

This study tests whether adding two different drug combinations after radiation can help children and young adults (up to age 21) with high-grade gliomas, including DIPG, live longer. One group receives ribociclib plus everolimus; another gets ribociclib plus temozolomide. The go…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This study tests a new drug called HRS-6719 in people with advanced solid tumors that lack a gene called MTAP. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 120 participants will take part across multiple centers.

This study tests whether a 1-week course of partial breast radiation is safe and effective for women who have had a breast cancer recurrence after prior whole-breast radiation. Participants will receive targeted radiation after breast-conserving surgery to remove the new tumor. T…

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…

This study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The trial will enroll about 355 adults and is the first time this drug i…

This phase 1 trial is testing whether injecting tiny radioactive beads (Y-90) into the right side of the liver can shrink tumors and make the left side grow larger, so more patients with colorectal cancer liver metastases can have potentially curative surgery. The study will enro…

This early-phase trial is testing a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test different dosing schedules in patients with esophageal or head and neck cancers. Ab…

This study tests a new drug called neladalkib (NVL-655) in people with advanced ALK-positive non-small cell lung cancer and other solid tumors. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well it shrinks tumors. Up to 840 participants will be en…

This study tests whether people with brain metastases from solid tumors can avoid radiation therapy if their brain tumors shrink or stay stable with systemic treatments like immunotherapy, targeted therapy, or chemotherapy. About 45 participants will be monitored with regular bra…

This early-stage trial is testing whether the drug sotorasib can get into KRAS G12C+ brain tumors and how safe and effective it is. Sixteen adults with these tumors who are already scheduled for brain surgery will receive the drug. Researchers will measure how much drug reaches t…

This study is for women with advanced ovarian, fallopian tube, or peritoneal cancer whose tumors did not shrink enough with standard chemotherapy. Researchers are testing a new method called PIPAC, which delivers chemotherapy as a pressurized spray directly into the abdomen, comb…

This early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose,…

This study tests whether a 4-week ketogenic diet before liver surgery can reduce fat in the liver and lower the need for blood transfusions. About 124 adults with fatty liver and colorectal cancer that spread to the liver will either follow the diet or get standard dietary advice…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This phase 2 trial is testing a combination of three immune-boosting drugs (relatlimab, nivolumab, and ipilimumab) in 60 people with melanoma that has spread to the brain. The study includes both patients with and without symptoms from their brain tumors. The main goal is to see …

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…

This early study tests a new treatment for people with stage 4 solid tumors that have stopped responding to standard care. Patients receive an injection of iron-containing nanoparticles that travel to the tumor, then a machine creates a magnetic field to heat the particles and da…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This early-phase trial is testing an experimental oral drug called pidnarulex in 40 people with advanced solid tumors that have spread and stopped responding to standard treatments. The drug works by blocking an enzyme that cancer cells need to divide and repair their DNA. The st…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…

This early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…

This study tests a new treatment called EB-NK-301, which uses specially engineered immune cells (CAR NK cells) to target a protein called TROP2 found on many solid tumors. The trial enrolls 60 adults with advanced or metastatic cancers that have not responded to standard treatmen…

This study is testing whether a lower dose of radiation can effectively treat metastatic tumors that have a specific genetic change called an ATM mutation. The goal is to find the smallest effective dose to reduce side effects. About 45 adults with advanced cancer and an ATM muta…

This phase IIa trial tests a combination of a dendritic cell vaccine (targeting HER2/HER3 proteins) and the immunotherapy drug pembrolizumab (Keytruda) in 23 women with breast cancer that has spread to the brain. The vaccine aims to train the immune system to attack cancer cells,…

This study tests whether injecting a PD-1 inhibitor (tislelizumab or pembrolizumab) plus pemetrexed directly into the spinal fluid can help people with non-small cell lung cancer that has spread to the lining of the brain (leptomeningeal metastases). The trial will enroll 17 adul…

This phase 2 trial is testing a new drug, trastuzumab rezetecan, against an existing drug, trastuzumab deruxtecan, in 150 women with a common type of advanced breast cancer (HR-positive, HER2-low). The goal is to see which dose works best to slow cancer growth. Participants must …

This early-stage trial is testing a new drug called SKB107 in people with advanced solid tumors that have spread to the bones. The drug delivers a small amount of radiation directly to bone tumors. The study will enroll about 90 adults to check if the drug is safe, how it moves t…

This early-phase study is testing whether a combination of low-dose radiation to the whole brain, an immunotherapy drug (PD-1 inhibitor), and chemotherapy given directly into the spinal fluid can safely treat lung cancer that has spread to the lining of the brain and spinal cord.…

This study tests an experimental daily pill called REC-1245 in people with advanced solid tumors or lymphomas that have not responded to or are not eligible for standard therapies. The main goals are to find a safe dose and check if the drug can shrink tumors. About 170 adults wi…

This early-stage trial tests an experimental drug called BBO-8520 in 350 people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The drug is taken as a pill and aims to block cancer growth. The study will check for safety, side effects, and…

This early-phase trial is testing whether a combination of two drugs, atezolizumab and tiragolumab, can help control bladder cancer when given before surgery to remove the bladder and tumor. The study includes 10 adults with muscle-invasive bladder cancer who cannot take standard…

This phase 2 trial is testing the safety of abemaciclib (Verzenio) combined with hormone therapy in people aged 70 and older with hormone receptor-positive metastatic breast cancer that has worsened after prior treatment with a similar drug. The study will enroll 43 participants …

This study tests whether using a 3 Tesla MRI during surgery for brain metastases helps surgeons remove tumors more completely. About 154 adults will be randomly assigned to standard surgery or surgery with the MRI. The goal is to see if the MRI leads to better tumor removal and f…

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This study tests a new drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink tumors. The…

This study compares two types of surgery to remove lung tumors that have spread from osteosarcoma (a bone cancer). One method uses a single large cut (open surgery), while the other uses several small cuts and a camera (keyhole surgery). The goal is to see which approach helps pa…

This early-stage trial tests a combination of low dose radiotherapy, focused radiation (SBRT), and the immunotherapy drug tislelizumab in people with large solid tumors that have not responded to standard treatments. The study aims to see if this approach is safe and tolerable. A…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This phase II trial tests a special way of delivering whole-brain radiation called pulsed reduced dose-rate (PRDR) along with the drug memantine to help protect memory and thinking in people with brain metastases. About 53 adults with solid tumors that have spread to the brain wi…

This study tests whether giving focused radiation before surgery for large brain metastases works better than giving it after surgery. About 146 adults with solid tumors and one large brain metastasis will be randomly assigned to one of the two timing schedules. The main goal is …

This early-phase trial tests whether injecting methotrexate-loaded vesicles (tiny drug-carrying particles made from patients' own tumor cells) into the spinal fluid can safely treat lung cancer that has spread to the brain lining. About 14 adults who have failed standard treatmen…

This early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…

This study compares two ways of giving the chemotherapy drug 5-FU to people with head and neck cancer that has spread or come back after prior treatments. One group gets the drug over two days every two weeks, the other over four days every three weeks. The goal is to see which s…

This study compares two ways to prevent brain tumors from growing back after surgery. One group gets a chemotherapy wafer (GLIADEL) placed directly where the tumor was removed, while the other group receives radiation treatment within six weeks. The trial aims to see if the wafer…

This early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…

This pilot study is testing a precise form of radiation called proton SBRT for people with cancer that has spread to the spine and cannot be treated effectively with standard photon radiation. The study will enroll 12 participants and aims to see if the treatment can be delivered…

This early-phase study tests a new drug called DR30206 in about 216 adults with advanced or metastatic solid tumors who have no other treatment options. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive t…

This study tests a new treatment using natural killer (NK) cells, a type of immune cell, for adults with aggressive brain tumors that have not responded to standard therapies. The NK cells are grown in a lab and then given through a vein and directly into the brain. The main goal…

This study is for people with endometrial cancer that has come back or spread to a few other spots. It tests a new drug called cadonilimab given together with standard chemotherapy and radiation. The goal is to see if this combination can shrink tumors and help people live longer…

This early-stage trial tests a new drug called KGX101, given alone or with another immunotherapy (envafolimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 57 p…

This early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This study tests a higher dose of a targeted therapy (EGFR-TKI) combined with two other drugs for people with advanced lung cancer that has spread to the lining of the brain and worsened on standard treatment. About 30 participants will receive the triple combination to see if it…

This study tests whether precise, high-dose radiation (stereotactic radiotherapy) can restore the effectiveness of anti-PD1 immunotherapy in patients with metastatic solid tumors. Participants are those who initially responded well to immunotherapy for at least 6 months but then …

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…

This study tests whether using a smaller, more precise radiation target for spinal tumors can control cancer just as well as treating the whole vertebra. One hundred adults with spine metastases will be randomly assigned to standard or smaller-target radiation. The goal is to see…

This early-stage study is testing the safety of two devices (NovoTTF-200M and NovoTTF-200A) that deliver electric fields to treat spinal tumors that have not responded to standard treatments like surgery or radiation. About 30 participants will receive the treatment, either alone…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This study tests whether two drugs, zanzalintinib and pembrolizumab, can help control advanced soft-tissue sarcoma that has spread. About 20 adults with specific sarcoma types will receive the combination. The main goal is to check safety and see if the treatment slows tumor grow…

This phase 2 trial tests the drug IMC-001 in 30 adults with advanced solid tumors that have a high number of genetic mutations (TMB-H). Participants receive the drug by IV every two weeks. The main goal is to see if the drug shrinks tumors. Researchers will also monitor side effe…

This early-stage study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…

This early-phase study is testing two drugs together — alpelisib and pembrolizumab — in people with metastatic breast cancer or melanoma that has spread to the brain or other organs. The main goal is to find a safe dose and see what side effects occur. Up to 50 adults whose cance…

This study tests an oral drug called larotrectinib in people aged 16 and older whose advanced solid tumors have too many copies of the NTRK gene. The drug blocks enzymes that help cancer cells grow. Researchers will measure how many patients' tumors shrink or disappear.

This early-phase study tests a personalized treatment called GT101 for adults with advanced solid tumors that have spread or come back. Doctors take immune cells from the patient's own tumor, grow them in a lab, and infuse them back after mild chemotherapy. The goal is to see if …

This phase II trial is testing two oral drugs, binimetinib and encorafenib, in 35 adults with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The study aims to see if this combination can control the disease and improve surviva…

This early-stage trial is testing a new drug called INCB123667, taken as a tablet, in people with advanced solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with other cancer therapies. The main goals are to…

This study tests whether two drugs, pembrolizumab and lenvatinib, can shrink brain tumors in people with breast cancer, lung cancer, or other solid tumors that have spread to the brain. About 87 participants will receive the combination therapy. The goal is to see how well the tr…

This phase 2 trial is testing whether giving systemic therapy first, followed by focused radiation (stereotactic radiosurgery), can better control brain metastases. About 316 adults with brain metastases that are low-risk will receive standard cancer drugs, then some will get rad…

This early-stage trial tests a new drug called CBP-1019 combined with standard chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have not responded to prior treatments. The goal is to find safe and effective doses. About 128 participants wi…

This early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…

This study tests two drugs, abemaciclib and bicalutamide, together in people with a type of metastatic breast cancer that has spread and is positive for androgen receptors but negative for HER2. The goal is to find the safest dose and see if the combination can control the diseas…

This study tests a new drug called NBQ72S in 10 people with breast cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastases). Participants receive the drug every 28 days. The goal is to see if the drug can control the cancer and improve survival…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This study tests whether giving radiation in one session or several sessions works better for people whose cancer has spread to the brain. About 90 adults with brain tumors between 2 and 4 cm will be randomly assigned to one of two radiation approaches. The goal is to see which m…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This study tests a treatment called electrochemotherapy for people with tumors in organs like the liver or pancreas that cannot be removed by surgery. The treatment uses short electrical pulses to help chemotherapy drugs enter cancer cells more effectively. The goal is to shrink …

This study is for people with cancer that has spread to the spine. It tests whether adding a procedure called vertebroplasty (which repairs broken spine bones) to standard radiation and immunotherapy can help prevent fractures and improve survival. About 200 participants will rec…

This early-phase trial is testing a new drug called DB-1317 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and then expanding to see if the drug shows any signs of shrinking tumors. About 2…

This study tests a new way to treat stomach cancer that has spread to the lining of the belly. Doctors will use a robot to remove visible cancer and then deliver heated chemotherapy directly into the abdomen during surgery. The goal is to help patients recover faster and have few…

This phase II trial is testing whether an anti-viral drug called valganciclovir (Valcyte) can help treat breast cancer that has spread to the brain. The study includes 28 adults with progressive brain metastases who also have evidence of a common virus called CMV. Participants ta…

This study tests a combination of two drugs—lorlatinib (a daily pill) and ramucirumab (an IV infusion every three weeks)—in people with advanced ALK-rearranged non-small cell lung cancer. The first part finds the safest dose, and the second part checks if that dose helps keep the…

This study tests whether combining a targeted pill (adagrasib) with precise radiation (SRS) can control brain tumors in people with a specific type of advanced lung cancer (KRAS G12C mutation). About 30 adults with untreated brain metastases will receive both treatments. The main…

This phase III trial tests whether adding nitroglycerin patches to standard radiation therapy helps shrink brain tumors better than radiation alone in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). 74 participants will receive either radiatio…

This phase 2 trial is testing whether a combination of three drugs—nivolumab, ipilimumab, and cabozantinib—can help people with kidney cancer that has spread to the brain. The study will enroll 20 participants who have not had prior treatment for their brain metastases. The main …

This study looks at whether people with lung cancer that has spread to the brain can safely delay radiation therapy. Participants take alectinib, a targeted drug, either alone or with focused radiation. The goal is to see if starting with just the drug keeps the brain cancer unde…

This study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…

This trial is testing a new approach for people with head and neck cancer that has come back or spread and cannot be removed. It combines a device called DaRT, which is a tiny radioactive seed placed directly into the tumor, with the immunotherapy drug pembrolizumab (Keytruda). T…

This phase 2 trial tests whether adding a chemotherapy drug (thiotepa) directly into the spinal fluid can prevent glioblastoma from spreading to the brain and spinal cord lining. The study enrolls 38 newly diagnosed patients whose tumors touch brain fluid spaces or whose surgery …

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This phase 3 trial tests two ways to treat lung cancer that has spread to the brain. One group gets targeted radiation to each tumor plus a drug (bevacizumab) that starves tumors of blood. The other group gets whole-brain radiation that tries to avoid the memory centers. The stud…

This early-stage trial tests a new mRNA vaccine called ABO2102, designed to target cancers with specific KRAS mutations. About 101 adults with advanced solid tumors will receive the vaccine alone or with another drug (Sintilimab). The study focuses on safety and how the body resp…

This early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early si…

This trial is testing a higher, every-other-day dose of the drug furmonertinib in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). The study will compare this high-dose schedule …

This study tests a new oral drug called VT3989, alone or with other cancer drugs, in people with advanced solid tumors, mesothelioma, or non-small cell lung cancer that hasn't responded to standard treatments. The trial has two phases: first, finding the safest dose, then expandi…

This study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…

This study is for people with metastatic breast cancer that has spread to the brain, with at least two brain tumors. Participants receive an immunotherapy drug called pembrolizumab every three weeks, plus a precise, one-time radiation treatment to just one of the brain tumors. Th…

This study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…

This study tests whether giving cancer patients a targeted therapy that matches a specific gene change in their tumor can help shrink or control the cancer. It includes 720 adults with advanced solid tumors, multiple myeloma, or non-Hodgkin lymphoma who have no standard treatment…

This early-phase trial tests whether deferoxamine, a drug given directly into the spinal fluid, is safe for people with leptomeningeal metastases—cancer that has spread to the lining of the brain and spinal cord. Researchers will test different doses in 35 adults with solid tumor…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This phase 2 trial tests a combination of pemetrexed (given into the spinal fluid) and a tyrosine kinase inhibitor for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis) after the d…

This phase 2 trial tests whether adding the drug narlumosbart and precise radiation therapy to standard first-line treatment can help people with advanced non-small cell lung cancer that has spread to the bones. The study will enroll 27 adults who have not had prior systemic ther…

This early-phase trial is testing a new way to give the cancer drug T-DXd (Enhertu) — as a shot under the skin instead of an IV drip. The study will enroll 76 adults with metastatic solid tumors to find the safest dose and see how well the body handles it. Researchers will also c…

This early-phase trial tests CPO301, a drug designed to seek out and attack cancer cells that have a protein called EGFR on their surface. About 132 adults with advanced solid tumors (including lung, breast, and head & neck cancers) will receive the drug by IV every three weeks. …

This study is testing whether giving an extra 'boost' of radiation to spinal tumors that have spread from other cancers can better control the tumor, reduce pain, and limit side effects. The trial will enroll 108 adults with confirmed or suspected solid tumors that have spread to…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

This study tests a procedure called pulmonary suffusion, which delivers the chemotherapy drug cisplatin directly to the lungs through a minimally invasive method. The goal is to control any remaining cancer cells after surgery or ablation in patients with sarcoma or colorectal ca…

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This study tests whether adding four drugs (gefitinib, trametinib, disulfiram, and sunitinib) to standard chemotherapy helps people with osteosarcoma that has spread. About 45 participants with newly diagnosed or advanced disease will be enrolled. Researchers will check if the co…

This early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses an…

This early-phase study tests a new drug called CCI-001 in people with advanced solid tumors that have come back or spread. The main goals are to check the drug's safety and find the best dose. About 70 participants will receive CCI-001 alone or with standard chemotherapy drugs li…

This early-stage trial is testing a new drug called MTI-301 in 42 adults with advanced solid cancers that have spread or can't be removed and haven't responded to standard treatments. The drug blocks an enzyme called SCD1, which some cancers use to grow and spread. The main goals…

This study tests an experimental oral drug called FMC-376 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The trial has three parts: first, finding the safest dose; then, checking how well th…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This early-phase study tests a new drug called BH3120, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 245 p…

This early-phase trial is testing a new drug called DCSZ11 alongside standard chemotherapy or immunotherapy in 9 people with advanced or metastatic solid tumors, including head and neck cancer. The main goal is to see if the combination is safe and whether it can shrink tumors. B…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This study tests two treatments for people whose cancer has spread to the brain and is growing despite prior therapy. One group receives palbociclib alone; the other gets palbociclib plus pembrolizumab. The goal is to see if these drugs can shrink or stabilize brain tumors. About…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This study is testing a bone marrow transplant from a half-matched family donor for people with high-risk solid tumors that have come back or not responded to treatment. Participants receive mild chemotherapy and radiation before the transplant, along with drugs to prevent reject…

This Phase 2 trial tests a drug called belzupacap sarotalocan (AU-011) for people whose cancer has spread to the choroid, the layer of blood vessels in the eye. The drug is injected into the eye and then activated with a laser. The study aims to see if it is safe and can shrink o…

This early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …

This study compares two radiation therapies for people with 4 to 15 brain metastases from cancer: stereotactic radiosurgery (SRS), which is done in 1-2 sessions, versus whole-brain radiotherapy (WBRT), which takes 10 sessions. The goal is to see if SRS offers similar survival wit…

This study tests whether adding the drug sarilumab to chemotherapy (capecitabine) can eliminate tiny amounts of cancer left behind after standard treatment in people with triple negative breast cancer, a very aggressive type. The goal is to prevent the cancer from coming back and…

This early-phase trial tests whether giving two standard chemotherapy drugs (5FU and oxaliplatin) directly into the abdominal cavity is safe for people with colorectal cancer that has spread only to the peritoneal lining. About 24 adults will receive the drugs through a catheter …

This study is for people whose brain metastases have returned after initial radiation. It combines either laser ablation or surgery with a second round of targeted radiation. The goal is to control the disease and monitor side effects in 155 participants.

This early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see i…

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…

This study tests whether giving a single dose of radiation before surgery for brain metastases can lower the chance of cancer spreading to the lining of the brain, compared to five doses after surgery. About 200 adults with brain tumors that can be removed will take part. The goa…

This study tests a new drug called JK06, designed to seek out and attack cancer cells while sparing healthy ones. It is for adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the safest dose and see if the drug can shrin…

This study tests a procedure called chemoembolization for people with non-small cell lung cancer or lung tumors that have spread from other cancers. Doctors inject chemotherapy directly into the artery feeding the tumor and then block that artery with tiny beads. This traps the c…

This early-phase trial is testing an investigational drug called risvutatug rezetecan in 15 people with recurrent glioblastoma or brain metastases. The drug is designed to seek out and deliver a cancer-killing payload to tumor cells. The study first measures how much drug gets in…

This phase 2 study is testing stereotactic body radiation therapy (SBRT) for people with non-small cell lung cancer or other cancers that have spread to the lung. Instead of daily radiation for weeks, participants receive high doses in just 3 to 10 sessions over 1 to 2 weeks. The…

This phase 2 trial tests whether adding cediranib or ceralasertib to olaparib can overcome resistance in BRCA-mutated advanced breast cancer. About 60 participants with HER2-negative, BRCA-positive tumors that have progressed on prior therapy will receive one of the two drug comb…

This study is for people with metastatic melanoma whose cancer has started growing in a few spots despite treatment. Researchers want to see if giving high-dose, precise radiation to those spots can delay further spread. About 52 adults will take part, and the main goal is to see…

This early-stage trial is testing a new chemotherapy drug called TR-002 in about 52 people with advanced solid tumors, including pancreatic cancer that has stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This early study tests whether injecting two cancer drugs (pemetrexed and bevacizumab) directly into the spinal fluid is safe for people with a specific type of lung cancer that has spread to the lining of the brain. The trial will enroll 19 adults whose cancer has worsened despi…

This pilot study tests whether giving precise, high-dose radiation to all visible tumors (up to 10) can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread. About 28 adults with 3-10 metastases will receive radiation over 3 weeks while…

This early-phase trial is testing MBRC-101, a drug that seeks out cancer cells and delivers a chemotherapy payload directly to them. It is for people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then check f…

This early-phase study tests HLX37, a new drug that targets two cancer growth pathways (PD-L1 and VEGF) at once, in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Up to 254 par…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This early-phase study tests a new oral drug, NVL-330, in about 200 adults with advanced or metastatic non-small cell lung cancer that has specific HER2 mutations. The goal is to find the safest and most effective dose and see if the drug can shrink tumors. Participants must have…

This study tests a drug called repotrectinib in 20 people with a specific type of lung cancer (ROS1-positive NSCLC) that has spread to the brain. The main goal is to see if the drug can shrink or eliminate brain tumors. Participants will take the drug by mouth, and doctors will m…

This early-stage trial is testing a new drug called PRTH-101, alone or with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will enroll about 270 people and focus on safety, do…

This study compares bevacizumab (Avastin) to standard steroid treatment (dexamethasone) as the first therapy for people with brain radiation necrosis—a side effect of radiation therapy for brain tumors. About 408 participants with high-grade glioma or brain metastases will be ran…

This study is testing a highly precise radiation method called SBRT for people with cancer that has spread to the spine. The goal is to deliver strong radiation doses while protecting nearby healthy tissue. Researchers will track side effects and how well the treatment controls t…

This early-stage trial tests a new drug called SLV-324 in about 70 people with metastatic solid tumors that have worsened after standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the body …

This study is for people with HER2+ breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease). It combines targeted drugs (tucatinib, trastuzumab, capecitabine) with radiation to the brain or spine. The goal is to see if this approach helps…

This study tests a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The trial will first find the safest dose, then expand to…

This study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …

This study tests a combination of three drugs (trastuzumab-deruxtecan, capecitabine, and bevacizumab) as a first treatment for people with HER-2 positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see how well the drugs shrink tumors. About …

This trial tests an experimental drug called CP-383 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The drug is taken daily by mouth and works by blocking a process cancer cells need to grow. The study …

This early-stage trial tests whether combining high-intensity focused ultrasound (HIFU) with immune checkpoint inhibitors (ipilimumab and nivolumab) is safe and feasible for people with metastatic or unresectable cancer that has worsened after standard treatments. 24 adults will …

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This phase II trial tests whether adding lovastatin, a common cholesterol-lowering drug, to the immunotherapy pembrolizumab can help shrink tumors in people with head and neck cancer that has returned or spread. The study will enroll 28 adults whose tumors express PD-L1. Research…

This study tests a treatment using a patient's own immune cells (called tumor-infiltrating lymphocytes or TILs) combined with chemotherapy and interleukin-2 for people with advanced cutaneous squamous cell carcinoma or Merkel cell carcinoma who have already tried immunotherapy. T…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intrav…

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mut…

This study is tracking 600 people with brain tumors who receive GammaTile therapy during surgery. GammaTile is a device that delivers radiation directly to the tumor site to help prevent regrowth. Researchers are measuring how long tumors stay under control and how patients feel …

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This pilot study tests a special PET/MRI scan that uses a radioactive tracer to find HER2+ breast cancer that has spread to the brain. The scan aims to show whether the cancer cells take up the tracer, which might predict if they will respond to the standard drug trastuzumab deru…

This study tests a new type of PET/MRI scan to see if it can better tell the difference between a growing brain tumor and changes caused by radiation or immunotherapy. About 30 adults with brain metastases who have had radiation in the last 2 years will get a single 3-hour scan s…

This study is testing whether a new contrast agent called gadopiclenol (VUEWAY) can improve MRI scans to detect leptomeningeal disease (LMD), a condition where cancer spreads to the lining of the brain and spinal cord. Researchers will compare it to the standard contrast agent ga…

This study tests whether a special PET scan using a radioactive tracer called 68Gallium-DOTATATE can better detect thyroid cancer that has spread and no longer responds to standard radioactive iodine therapy. About 54 adults with metastatic thyroid cancer will receive one injecti…

This study looks at whether adding an early PET scan right after the injection can better tell the difference between a brain tumor coming back and damage from radiation therapy. About 50 adults with brain metastases who already need a PET scan will get an extra 15-minute scan ri…

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…

This study tests a new type of PET/CT scan that uses a radioactive tracer called 68Ga-ABS011 to detect HER2, a protein found on some cancer cells. The goal is to see if this scan can more accurately determine HER2 status in people with metastatic breast cancer or other solid tumo…

This early-phase study tests a radioactive tracer called [68Ga]Ga-ABY-025 for PET scans in 30 adults with advanced HER2-positive cancers (breast, gastric, head/neck, esophageal). Participants receive the tracer and a PET/CT scan before or during standard HER2-targeted therapy. Th…

This study is testing a new, quick MRI technique called Magnetic Resonance Fingerprinting (MRF) to better tell the difference between a brain tumor coming back and damage from radiation therapy (radiation necrosis). About 90 people will take part, including healthy volunteers, pa…

This study aims to develop a blood test that detects RNA from tiny particles (exosomes) to predict if prostate cancer has spread to the bones. Researchers will analyze blood samples from 1,000 men with newly diagnosed prostate cancer and compare results with PSMA PET scans. The g…

This study tests a new type of PET scan that uses a special tracer (Ga68-PSMA) to see if it can tell the difference between a growing tumor and radiation damage in people with brain metastases from lung cancer, melanoma, or breast cancer. About 100 adults who have had radiation t…

This early-stage trial is testing a new radioactive tracer called 68Ga-FXX489 (NNS309) for PET/CT scans. The goal is to see if it can safely and accurately detect tumors and their spread in 30 adults with suspected cancer. Researchers will measure how the tracer moves through the…

This study tests a radioactive tracer called FET that lights up brain tumor cells on a PET scan. Researchers want to see if FET can better detect whether a brain tumor has come back after treatment, and help tell high-grade from low-grade tumors. About 199 people with known or su…

This study compares whole body diffusion-weighted MRI (DWI) to standard FDG PET/MRI scans in 30 adults with metastatic cancer. The goal is to see if DWI can spot cancer lesions as well as the PET scan, which uses a radioactive tracer. Participants will undergo both scans, and res…

This study aims to see if a special MRI scan called CEST can accurately tell apart radiation damage from tumor growth in people with lung cancer that has spread to the brain. About 60 adults who have had radiation therapy for brain metastases and show new changes on follow-up MRI…

This phase I/II trial tests a radioactive tracer called 64Cu-GRIP B, which targets granzyme B—a substance released by immune cells. By using PET scans, researchers hope to see immune activity in tumors and predict whether immunotherapy will work. The study involves about 91 adult…

This study tests a special MRI technique to help doctors tell whether an enlarged spot in the brain after radiation is the tumor growing back or harmless scar tissue from the radiation. About 100 adults with brain metastases who had radiation will get this MRI before any surgery.…

This early-phase trial is testing whether a new radioactive tracer called 18F-Clofarabine (CFA) can be used in PET scans to measure an enzyme activity in cancer cells that may predict how well certain drugs like gemcitabine work. Four adults with metastatic cancer will receive th…

This study compares a special PET scan (68Ga-PSMA) with standard CT scans to see which better detects where kidney cancer has spread in 300 adults with advanced disease. Participants will receive both scans, and doctors will check if the PET scan changes treatment plans. The goal…

This study tests whether using two contrast agents (gadolinium and ferumoxytol) in one MRI session can improve the detection and diagnosis of brain and central nervous system abnormalities. About 150 participants with neurological symptoms or known brain lesions will undergo imag…

This early-phase study is testing a new radioactive tracer for PET scans that may better detect non-small cell lung cancer that has spread to the brain. About 20 adults with this type of lung cancer and brain metastases will receive the tracer and undergo imaging. The goal is to …

This trial tests whether a different way of closing the abdominal wall during liver tumor surgery can lower the chance of developing an incisional hernia. 140 patients will be randomly assigned to receive either the new 'short stitch' method or the traditional closure. Researcher…

This study tests whether the seizure drug levetiracetam (Keppra) can prevent first-time seizures in people with brain metastases located in the motor cortex. About 150 adults who have never had a seizure will be randomly assigned to take the drug or receive standard care. The goa…

This study tests a mobile app called PACT that helps people with advanced cancer talk about and plan the care they would want if they couldn't speak for themselves. The app involves patients and their loved ones in these discussions. Researchers want to see if the app is easy to …

This study is for people whose cancer has spread to the brain. It compares two types of whole brain radiation: one that avoids only the memory center (hippocampus) and one that also avoids other brain areas tied to thinking. The goal is to see which better preserves memory and co…

This Phase 2 trial tests a new type of radiation therapy designed to avoid key brain areas involved in memory and thinking. Sixty adults with 1 to 3 small brain metastases will receive cognitive-sparing stereotactic radiosurgery. The main goal is to see if this approach better pr…

This study tests whether three 15-minute hypnosis sessions can help people with persistent breathlessness from cancer, COPD, interstitial lung disease, or chronic heart failure feel more in control of their breathing. Researchers will measure changes using a standard questionnair…

This study tests a new program called EASE, which uses a simple writing exercise to help adults with advanced cancer manage their fear of the future and related trauma symptoms. The study will include 250 people with advanced solid tumors, glioblastoma, or certain ovarian or lung…

This phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …

This study tests whether group sessions that teach stress management skills can lower distress in people with cancer. About 400 adults with cancer who have moderate distress will take part. The program helps patients recognize and reduce stress in their daily lives.

This study tests whether giving spine radiation in one session or two sessions better prevents bone fractures in people with cancer that has spread to the spine. About 130 adults with spine tumors will receive either one or two focused radiation treatments. The goal is to find wh…

This study tests whether a very low dose of radiation (2 Gy) can relieve bone pain in people with multiple myeloma that has spread to the bones. The goal is to see if this gentler approach works as well as standard radiation but with fewer side effects and less disruption to chem…

This study is looking at whether combining two treatments — a minimally invasive procedure called percutaneous ablation and standard radiation therapy — can better relieve pain from bone cancer that has spread. Researchers will follow 120 people whose pain is not controlled by me…

This phase 2 trial tests whether a higher dose of radiation (40-50 Gy over 10 sessions) can better relieve pain from cancer that has spread to bones or other areas. Researchers hope to double the complete pain response rate at one month compared to standard doses. The study invol…

This study tests whether a group retreat using psilocybin (the active ingredient in magic mushrooms) can safely reduce anxiety and depression in people with incurable cancer. Participants will receive a pharmaceutical-grade psilocybin along with guided discussions to help them ga…

This study is testing whether it is safe to avoid giving the steroid dexamethasone before, during, and for three weeks after brain metastasis surgery. The goal is to see if patients can avoid the side effects of steroids without needing extra rescue doses. The trial will enroll 3…

This early-phase study tests a single dose of TLX090-Tx, a radioactive drug, in 33 adults with advanced cancer that has spread to the bones and causes pain. The goal is to find a safe dose and see if it can reduce pain. Participants must have at least one painful bone spot and ha…

This study looks at whether asking people with advanced cancer about their financial struggles each month can help reduce their worry and improve their quality of life. About 1,000 adults receiving treatment for advanced or metastatic cancer will be randomly assigned to either mo…

This study tests whether offering a palliative care consultation early—when patients with advanced cancer and bone metastases start radiotherapy—improves their satisfaction with care and quality of life. About 246 participants will be randomly assigned to receive either a tailore…

This study looks at whether a procedure called arterial embolization can reduce pain and improve quality of life in people with bone metastases (cancer that has spread to the bones). The procedure blocks blood flow to the tumor, which may shrink it and ease symptoms. Researchers …

This study tests whether having spine surgery and radiation on the same day helps people with painful spinal tumors recover physical function faster than the usual approach of surgery followed by radiation weeks later. About 100 adults with unstable spinal metastases will be rand…

This study tests whether combining psychoeducational sessions (like counseling and self-help strategies) with an open-label placebo can reduce fatigue in people with metastatic cancer. Participants will be assigned to one of three groups: education only, placebo only, or both. Th…

This study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better than standard radiation and help people feel better. About 37 adults with advanced solid tumors will receive this tre…

This study tests whether a single, precise dose of radiation (SBRT) can relieve pain and improve quality of life in people with cancer that has spread, compared to the usual multiple sessions of standard radiation. About 1,500 participants with metastatic tumors causing symptoms …

This study tests whether adding a non-opioid painkiller (ketorolac) to standard opioid pain medication can reduce the amount of opioids needed after preventive femur surgery. The study includes 60 adults with bone lesions from cancer who are getting a metal rod placed in the thig…

This study tests whether combining three treatments—kyphoplasty (spine stabilization), radiofrequency ablation (heat to destroy tumor tissue), and standard radiation—can better reduce pain from spine tumors. About 70 adults with cancer that has spread to the middle or lower back …

This study tests a new type of whole brain radiation that spares healthy tissue, aiming to improve quality of life and reduce symptoms for people with brain metastases. About 41 adults with solid tumors and brain metastases will receive this radiation plus a standard drug. Resear…

This study tests a new way to give radiation to people with cancer that has spread to the spine and is pressing on the spinal cord. The goal is to see if giving a slightly higher dose of radiation to the tumor while protecting the spinal cord is safe. About 60 adults with this co…

This study tests whether adding cryoablation (a procedure that freezes and kills cancer cells) to standard radiation therapy provides better pain relief for people whose cancer has spread to their bones. About 40 participants with various cancers will be split into two groups: on…

This study tests a procedure that uses radiofrequency heat to destroy spine tumors, followed by bone cement to stabilize the spine. Sixteen people with cancer that has spread to the spine will receive the treatment. The goal is to see if the tumors become less active on PET scans…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This study tests whether electronic surveys can help people with advanced cancer report their symptoms and care needs, so their doctors can connect them to palliative (supportive) care services sooner. About 90 adults with incurable solid tumors will participate. The goal is to s…

This early trial tests whether minoxidil (Rogaine) — applied to the scalp or taken as a pill — can help with hair loss caused by hormone therapy in breast cancer patients. About 50 women with stage I-IV breast cancer who report hair thinning since starting endocrine therapy will …

This study tests a new type of radiation called proton GRID for people with large tumors (at least 4.5 cm) that cannot be removed by surgery or have spread. The goal is to safely relieve symptoms like pain. About 24 adults will receive three radiation treatments, and researchers …

This early-phase trial is testing whether a minimally invasive procedure using special light-activated nails can help stabilize the pelvis in people whose cancer has spread to the bone around the hip socket. Fifty adults with confirmed cancer and visible pelvic metastases will be…

This study tests a parenting support program for 120 parents with advanced cancer and their spouses. The program aims to reduce parenting worries, improve family communication about cancer, and boost emotional wellbeing. Participants must have a child aged 4-16 living at home and…

This phase 2 trial tests whether adding olanzapine to standard care helps manage appetite loss in head and neck cancer patients undergoing chemoradiation. About 66 adults will receive either olanzapine plus standard symptom management or standard care alone. The main goal is to s…

This study tests whether a cream containing tretinoin (a form of vitamin A) can prevent or reduce the acne-like rash that often occurs in patients taking certain cancer drugs. About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo …

This study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study tests a lab technique called pharmacoscopy that quickly checks which drugs work best on a patient's own brain metastasis tissue. About 102 adults with brain metastases and few treatment options will have their tumor samples tested. The goal is to see if using this test…

This pilot study is exploring whether a one-time sample of spinal fluid (taken via a lumbar puncture) can detect cancer DNA in patients with solid tumors that have spread to the brain or spinal cord. Researchers will enroll 60 participants across three groups: those with leptomen…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study from Mayo Clinic is looking at how T cells (a type of immune cell) change during anti-PD-1 immunotherapy in people with advanced melanoma, lung cancer, or other solid tumors. Researchers will collect blood and tissue samples from 500 participants to measure specific ma…

This observational study tracks over 10,000 people with advanced or metastatic cancer to understand why outcomes vary by race and background. Researchers collect social, genetic, and treatment data from patients at four cancer centers. The goal is to identify factors—like social …

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is observing about 800 adults with advanced breast cancer (HER2-positive, low, or ultralow) who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers are tracking how long patients stay on the drug before switching treatment…

This study uses genetic testing of brain tumors from children, adolescents, and young adults (ages 1 to 39) with newly diagnosed high-grade glioma, including DIPG. The goal is to identify specific genetic changes in each tumor and then see if patients can join a treatment trial t…

This study looks at DNA and protein changes in tumor samples from 50 adults with aggressive or metastatic cancer. Researchers aim to find new markers for diagnosis and potential drugs. Participants provide blood, cheek swabs, and tissue from standard biopsies or surgeries.

This study is testing whether a smartwatch can track changes in walking and daily activities in people with bone cancer (osteosarcoma or metastatic bone disease). The goal is to see if the watch can help doctors spot problems early and personalize care. About 60 participants will…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study looks at genetic changes in patients with colorectal cancer that has spread only to the liver and cannot be removed by surgery. Researchers will perform liver transplants and then analyze tumor genetics and blood samples to better understand why the cancer spreads and …

This study looks at whether precise radiation (SRS or SBRT) can help preserve thinking and memory in people with multiple brain tumors that have spread from other cancers. About 90 adults with 1 to 10 brain metastases will get radiation and then take thinking tests over 4 months.…

This study looks back at 600 patients who had surgery for a broken or about-to-break upper thigh bone caused by cancer that spread from elsewhere. Researchers will compare two surgical methods—a metal rod inside the bone or a replacement joint—to see which one leads to fewer comp…

This study is testing whether a special PET scan (using 18F-Fluciclovine) can help doctors see if brain tumors are responding to radiation treatment. About 46 adults with brain metastases will get the scan before and after stereotactic radiosurgery. The goal is to find a better w…

This study tests a special brain-mapping grid placed during surgery to better identify areas that control movement and speech. Researchers will compare this method with standard techniques in 75 adults with brain tumors. The goal is to see if the new grid helps surgeons avoid dam…

This study is testing whether a 15-minute app called Brainlab Cognition can be used in busy brain tumor clinics to track memory, attention, and other thinking skills. Researchers will also collect quality-of-life reports electronically from patients. The goal is to see if this ap…

This study is building a registry of 500 children, teens, and young adults (ages 1-39) diagnosed with cancer. Participants will complete physical and mental function tests, surveys, and provide blood samples over time. The goal is to learn how cancer and its treatments affect agi…

This study is testing a simple scoring system to predict whether people with metastatic cancer will survive at least 30 days after starting palliative radiation therapy. The score uses lab results, emergency room visits, and cancer type. About 214 adults will join to see if the t…

This pilot study will test whether a special PET/MRI scan can detect real-time artery inflammation in the heart after chest radiation therapy. Ten adults with stage II-III or limited stage IV cancer who are at high risk for heart problems will be scanned before and 6 months after…

This registry is collecting information from 2,000 people with metastatic cancer who are receiving radiation therapy as part of their standard care. Researchers will gather clinical data and patient-reported outcomes to better understand how radiation affects cancer outcomes. The…

This study looks at whether a simple blood test can find tiny bits of cancer DNA left after surgery for stage III colorectal cancer. The goal is to see if this test can help doctors decide who really needs extra chemotherapy and who can skip it. About 590 people will give blood s…

This study tests whether a brain mapping technique called navigated transcranial magnetic stimulation (nTMS) can help doctors plan radiation therapy better for people with brain metastases near the motor cortex. About 30 patients who had surgery for a brain tumor will get both a …

This study tests whether a new screening tool can help people with advanced lung cancer better understand their illness and treatment goals. About 100 patients will either use the tool or receive usual care. The goal is to see if the tool leads to more informed decisions that mat…

This study looks at people with advanced lung cancer who have lived at least three years after diagnosis and are no longer on chemotherapy. Researchers want to understand their health, quality of life, and social or financial challenges. Participants will fill out questionnaires …

This study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…

This study is testing a new radioactive tracer called [C-11]-CS1P1 that lights up inflammation in brain tumors during a PET scan. Researchers will scan 104 adults with primary or secondary brain cancers before and after treatment to see how inflammation patterns change. The goal …

This study is testing a special imaging agent called 18F-fluciclovine to see if it can detect how well radiation therapy is working on large brain tumors that have spread from other cancers. About 20 adults with at least one untreated brain tumor larger than 2 cm will get PET/CT …

This study collects health information from 500 adults with painful bone metastases that have spread from other cancers. Researchers aim to better understand the disease and track survival over time. No new treatments are given; participants simply share their medical data.

This study tests whether a special PET scan (EstroTEP) and blood tests can help doctors pick the best second-line treatment for people with ER-positive, HER2-negative metastatic breast cancer. About 300 participants will be assigned to either endocrine therapy or chemotherapy bas…

This pilot study is looking for better ways to see if endocrine therapy is working in people with a type of breast cancer called metastatic invasive lobular carcinoma. Researchers will use a special PET scan and blood tests to measure changes in estrogen signaling after 4 weeks o…

This study creates a registry for people with leptomeningeal disease, a rare condition where cancer spreads to the lining of the brain and spinal cord. Researchers will collect information on how the disease progresses, what treatments are used, and any side effects. The goal is …

This early study tests if a portable device that creates electric fields is safe and practical for people with breast or lung cancer that has spread to the lining of the spine. Only 5 participants will wear the device for at least 28 days. The goal is to see if the treatment is t…

This study is testing whether using simple blood tests to decide when to do scans is as effective as the usual approach of regular scans for people with advanced breast cancer. About 739 participants will be randomly assigned to either blood test monitoring or standard care. The …

This study looks at the fluid around the brain (cerebrospinal fluid) in people with breast cancer that has spread to the brain or its lining. Researchers collect this fluid to study the cancer's genetic material without needing surgery. The goal is to better understand why breast…

This study looks at whether regular MRI scans of the brain after radiation therapy can find cancer that has spread to the brain before it causes symptoms. About 60 adults with stage III non-squamous lung cancer will get brain MRIs at set times. The goal is to see if this monitori…

This study will follow 2500 cancer patients with bone metastases to better understand why some respond to radiation therapy and others do not. Researchers will collect data to build tools that predict pain relief and survival, and to create a platform for testing new treatments. …

This study tests whether doing radiation planning and treatment on the same day can better target fast-growing brain metastases. About 60 adults with brain tumors that grow at least 1mm per week will be randomly assigned to receive radiation with a 1mm or 0mm safety margin. The g…

This study looks at people with small intestinal neuroendocrine tumors that have spread and cannot be cured. It compares those who had surgery to remove the main tumor plus other treatments against those who had only other treatments. The goal is to see if surgery helps patients …

This study looks at tissue samples from 30 adults with stomach or esophageal cancer that spread to the brain. Researchers compare the genetic markers of the original tumor and the brain tumor to see if they differ. The goal is to better understand how these cancers change when th…

This study looks at how Y90 radioembolization, a radiation treatment for liver tumors that have spread from colorectal cancer, actually works inside the body. Researchers will collect small tissue samples (biopsies) from the liver after treatment to see how much tumor damage occu…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This observational study uses a special MRI technique with hyperpolarized carbon-13 pyruvate to see how brain tumors use energy. Researchers will measure metabolic byproducts in 25 adults with brain tumors before any treatment. The goal is to learn more about tumor metabolism, no…

This study collects tissue and blood samples from up to 5,000 cancer patients of all ages. The samples are used to create lab models, such as cell lines and animal models, to help scientists better understand cancer and test new treatments. Participants do not receive direct trea…

This phase 2 trial is testing whether CT and MRI scans can act as biomarkers to predict how patients with brain metastases respond to radiation therapy. About 90 adults with brain metastases who are scheduled for radiation will get scans before and after treatment. The goal is to…

This study aims to develop and test a new MRI technique to distinguish between actual tumor growth and changes caused by radiation treatment in people with brain metastases. Researchers will include both healthy volunteers and patients who have had stereotactic radiosurgery. The …

This study is testing whether a special smart shirt, called Hexoskin, can help monitor side effects in 100 patients receiving palliative radiotherapy for cancer that has spread. The shirt tracks heart rate, breathing, and activity levels. The goal is to see if it's practical to u…

This study asks brain cancer patients about their experience with telemedicine compared to in-person visits. Researchers want to learn if patients feel they receive good care through virtual appointments. The goal is to improve how care is delivered to people with brain tumors.

This study explores whether magnetic resonance spectroscopy (MRS) can be used to safely evaluate spinal cord lesions. Researchers will test the technique in healthy volunteers and patients with leptomeningeal disease who are receiving radiation. The main goal is to see if MRS is …

This study observes 100 adults with painful spinal metastases to see how doctors choose between two radiation types: standard palliative radiation (CRT) and a more precise, high-dose form (SBRT). Researchers will track pain relief, tumor control, and the reasons behind treatment …

This study looks at how well robotic biopsies can collect enough tissue to find genetic changes linked to lung cancer. About 40 adults at high risk for lung cancer or with suspected spread to the lungs will take part. The goal is to create a databank of genetic and medical inform…

This study looks at how much of the drug T-DXd enters brain tumors in people with HER2-positive brain cancers or glioblastoma. Thirty participants will receive T-DXd before surgery to remove a brain tumor, and researchers will measure drug levels in the tumor. The goal is to see …

This study is testing a new approach called Functional Precision Oncology for people with triple-negative or HR-low/HER2- breast cancer at high risk of early recurrence. Researchers will create personalized tumor models (in mice and lab dishes) from each patient's cancer to find …

This study looks back at medical records of 350 people with cervical cancer that has come back or spread to a few spots. The goal is to see how well treatments like radiation or surgery work, alone or with chemotherapy. Researchers want to find out which patients benefit most fro…

This study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems in the cancer cells make the drug radium-223 work better or worse. The goal is to help doctors choose the best treatment for each patient in …

This study is testing whether a small probe called a microdialysis catheter can be safely used during brain surgery to collect fluid samples from tumors. The goal is to measure biomarkers that could help doctors better understand and treat brain cancers like gliomas and metastati…

This study looks at how people with advanced cancer feel about stopping or reducing medications that may no longer help. Researchers will interview about 25 patients and survey 300 more to understand their attitudes and beliefs. The goal is to learn what factors influence their v…